Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy

被引：14

作者：

Brar, Gagandeep ^{[2
]}

Greten, Tim F. ^{[1
]}

Brown, Zachary J. ^{[2
]}

机构：

[1] NIH, Thorac & GI Malignancies Branch, Ctr Canc Res, Bldg 10,Room 3B43, Bethesda, MD 20892 USA

[2] NCI, Thorac & GI Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

来源：

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2018年 / 11卷

关键词：

hepatocellular carcinoma; immune checkpoint inhibitor; immunotherapy; LIVER-TRANSPLANT RECIPIENT; ADOPTIVE CELL TRANSFER; PHASE-I TRIAL; T-CELLS; ALPHA-FETOPROTEIN; INTRATUMORAL INJECTION; PERIPHERAL-BLOOD; SUPPRESSOR-CELLS; PEPTIDE VACCINE; CLINICAL-TRIAL;

D O I：

10.1177/1756284818808086

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Hepatocellular carcinoma (HCC) is a major cause of cancer-associated mortality worldwide and is expected to rise. Patients with early-stage disease may have a good prognosis with a 5-year survival rate of greater than 70%. However, the majority of patients are diagnosed with late-stage disease with a dismal overall survival rate of less than 16%. Therefore, there is a great need for advances in the treatment of advanced HCC, which for approximately the past decade, has been sorafenib. Immunotherapy is an evolving cancer treatment and has shown promise in treating patients with advanced HCC. In this review, we discuss the current standard of care for advanced HCC and then discuss the evolving role of immunotherapies.

引用

页数：12

共 84 条

[1] Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial. [J].

Abou-Alfa, Ghassan K. ;

Meyer, Tim ;

Cheng, Ann-Lii ;

El-Khoueiry, Anthony B. ;

Rimassa, Lorenza ;

Ryoo, Baek-Yeol ;

Cicin, Irfan ;

Merle, Philippe ;

Park, Joong-Won ;

Blanc, Jean-Frederic ;

Bolondi, Luigi ;

Klumpen, Heinz Josef ;

Chan, Stephen Lam ;

Dadduzio, Vincenzo ;

Hessel, Colin ;

Borgman-Hagey, Anne E. ;

Schwab, Gisela ;

Kelley, Robin Kate .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)

[2] Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease [J].

Acloque, Herve ;

Adams, Meghan S. ;

Fishwick, Katherine ;

Bronner-Fraser, Marianne ;

Angela Nieto, M. .

JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (06) :1438-1449

[3]

[Anonymous], JAMA ONCOL

[4]

[Anonymous], 2018, J CLIN ONCOL S

[5]

[Anonymous], J HEPATOL

[6]

[Anonymous], GASTROENTEROLOGY

[7]

[Anonymous], 2017, ASCO ABSTR

[8]

[Anonymous], J CLIN IMMUNOL

[9] Increase in CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis [J].

Arihara, Fumitaka ;

Mizukoshi, Eishiro ;

Kitahara, Masaaki ;

Takata, Yoshiko ;

Arai, Kuniaki ;

Yamashita, Tatsuya ;

Nakamoto, Yasunari ;

Kaneko, Shuichi .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (08) :1421-1430

[10] CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia [J].

Brentjens, Renier J. ;

Davila, Marco L. ;

Riviere, Isabelle ;

Park, Jae ;

Wang, Xiuyan ;

Cowell, Lindsay G. ;

Bartido, Shirley ;

Stefanski, Jolanta ;

Taylor, Clare ;

Olszewska, Malgorzata ;

Borquez-Ojeda, Oriana ;

Qu, Jinrong ;

Wasielewska, Teresa ;

He, Qing ;

Bernal, Yvette ;

Rijo, Ivelise V. ;

Hedvat, Cyrus ;

Kobos, Rachel ;

Curran, Kevin ;

Steinherz, Peter ;

Jurcic, Joseph ;

Rosenblat, Todd ;

Maslak, Peter ;

Frattini, Mark ;

Sadelain, Michel .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (177)

← 1 2 3 4 5 6 7 8 9 →